Composition comprising at least one water-soluble pharmaceutically acceptable salt of elafibranor having improved intestinal absorption
A composition comprising, as an active principle, a pharmaceutically acceptable salt of elafibranor, characterised in that the pharmaceutically acceptable salt of elafibranor is chosen from at least a salt of choline, of ethanolamine, or of diethanolamine, or of L-lysine, or of piperazine, or of calcium, or of tromethamine. More particularly, one or more embodiments relate to the use of elafibranor salts with a view to improving stability and solubility compared with elafibranor in the basic form thereof. These salts make it possible to establish pharmaceutical formulations in various advantageous forms as intravenous injections or formulations by enteral route having quicker and less variable absorption and consequently better bioavailability.
1. A composition comprising as an active principle a pharmaceutically acceptable salt of elafibranor,
wherein the pharmaceutically acceptable salt of elafibranor is the choline salt of elafibranor.
2. The composition according to claim 1 , wherein the composition is in a form suitable for enteral administration.
3. The composition according to claim 1 , wherein the composition is in a form suitable for parenteral administration.
4. The composition according to claim 3 , wherein the composition is in a form suitable for intravenous administration.
5. The composition according to claim 3 , wherein the elafibranor salt is micronised or has an amorphous structure.
6. The composition according to claim 3 , wherein the elafibranor salt is in the form of a powder for a soluble injectable preparation.
7. The composition according to claim 1 , wherein the composition is in a form suitable for subcutaneous administration.
8. The composition according to claim 1 , comprising at least one excipient chosen from binders, disintegrating agents, diluents, lubricants, surfactants, buffers, flow agents, dyes, flavourings, sweeteners, solvents or preservatives.
9. The composition according to claim 1 , comprising more than 50% particles with a size of less than or equal to 10 μm and all the particles with a size of less than 20 μm.
10. The composition according to claim 1 , wherein the elafibranor salt has a dissolution profile in simulated FaSSIF and FeSSIF media greater than 90% after 30 minutes.
11. The composition according to claim 1 , wherein the pharmaceutically acceptable salt of elafibranor (GFT505) is photostable.
12. The composition according to claim 1 , wherein the composition is for treatment of liver diseases.
13. The composition according to claim 12 , wherein the liver disease consists of non-alcoholic hepatic steatosis (NAFLD).
14. The composition according to claim 12 , wherein the liver disease consists of non-alcoholic steatohepatitis (NASH).
15. The composition according to claim 12 , wherein the liver disease consists of hepatic fibrosis.
16. The composition according to claim 12 , wherein the liver disease consists of cirrhosis.
17. The composition according to claim 12 , wherein the liver disease consists of hepatic autoimmune illnesses.